Lanreotide

Drug Profile

Lanreotide

Alternative Names: Angiopeptin; BIM 23014; BIM 23014C; BM 23014; Dermopeptin; Ipstyl; ITM-014; ITM-014N; Lanreotide acetate; Lanreotide Autogel; Lanreotide PRF; Somatulina; Somatuline; Somatuline Autogel; Somatuline Depot; Somatuline LA; Somatuline LP

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Tulane University
  • Developer Ipsen; Ipsen Biopharmaceuticals; Radboud University Nijmegen Medical Centre; Teijin Pharma
  • Class Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Growth hormone releasing factor antagonists; Thyrotropin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly; Gigantism; Malignant carcinoid syndrome; Neuroendocrine tumours
  • Phase II Pancreatic cancer
  • Discontinued Atherosclerosis; Breast cancer; Coronary artery restenosis; Diabetic retinopathy; Gastrointestinal cancer; Graves ophthalmopathy; Intestinal obstruction; Leiomyoma; Lung cancer; Polycystic kidney disease; Polycystic liver disease; Portal hypertension; Prostate cancer; Rheumatic disorders

Most Recent Events

  • 01 Jan 2017 Ipsen completes the phase III LANTERN trial for Acromegaly (In adults, In the elderly) in China (NCT02493517)
  • 07 Oct 2016 Adverse events data from the phase III open-label extension study of the CLARINET trial in Neuroendocrine tumour presented at the 41st European Society for Medical Oncology Congress (ESMO-2016) .
  • 01 Oct 2016 Teijin Pharma completes a phase II trial in Neuroendocrine tumours in Japan (JapicCTI-132375)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top